Compare Pfizer Inc (PFE) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Global X Uranium ETF — how do they compare? Pfizer Inc trades at $24.91 (market cap $142.14B), while Global X Uranium ETF trades at $40.98. The key difference: Pfizer Inc pays a 6.9% dividend while Global X Uranium ETF pays none, and Pfizer Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| PFE | URA | |
|---|---|---|
Market Cap | $142.14B | — |
Volume | 29,869,932 | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $28.56 | $61.81 |
52-Week Low | $23.29 | $36.45 |
Enterprise Value | $192.80B | — |
Dividend Yield | 6.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.
PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.
URA trades at $38.64, down 0.28% on the day, with technical indicators showing a bearish trend from moving averages but oversold RSI signals. The ETF holds $6.29 billion in assets and benefits from strong narratives around AI-driven power demand and nuclear energy expansion, though key financial ratios are not publicly detailed for the fund itself. Recent news highlights uranium's role in meeting data center electricity needs.
Outlook is supported by structural demand trends, but high expense ratios and competition from pure-play uranium funds pose risks. The fund's performance hinges on uranium price movements and policy developments, with current technical weakness suggesting caution in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
